ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 3146

Selective Deletion of a Pathogenic Subset Synovial Fibroblasts Attenuates Synovial Inflammation

Adam Paul Croft, Joana Campos, Andrew Filer, Francesca Barone and Chris Buckley, Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham, United Kingdom

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Animal models, Arthritis, Fibroblasts, inflammation and joint damage

  • Tweet
  • Email
  • Print
Session Information

Date: Wednesday, November 16, 2016

Title: Rheumatoid Arthritis – Animal Models II

Session Type: ACR Concurrent Abstract Session

Session Time: 9:00AM-10:30AM

Background/Purpose:  Despite their role as key effector cells driving synovial inflammation and joint damage, fibroblast like synoviocytes (FLS) have yet to be targeted therapeutically. Fibroblast activation protein (FAP) is a cell surface serine protease, known to be expressed at a low level in resting FLS but up-regulated during inflammation (1). Genetic deletion of FAP has been shown to protect against cartilage damage despite no protective effect on inflammation or bone erosion (2). The pathogenic role of FLS expressing FAP is currently unknown. To determine the pathogenic role of FAP expressing FLS in inflammatory arthritis we selectively deleted these cells using a conditional cell deletion stratergy during the effector phase of inflammatory arthritis.  

Methods:  We utilized a transgenic mouse in which FAP expressing cells were conditionally ablated (FAP-DTR3) by administration of diphtheria toxin in either in a prophylactic or therapeutic regime. Inflammatory polyarthritis was induced by the passive transfer of K/BxN serum into naïve mice. Mice were scored for clinical signs of arthritis and flow cytometry of digested synovial tissue was performed to determine the expression of fibroblast subsets .

Results:  We found that FAP expression in the human synovium predicts disease persistence in patients with early synovitis .FAP was dynamically expressed by FLS during inflammatory arthritis and defined a population of activated fibroblasts that co-express the lining layer marker Podoplanin (gp38). Therapeutic deletion of FAP+ cells during either the induction or peak phases of inflammatory arthritis significantly attenuated synovial inflammation leading to a reduction in the clinical severity of arthritis, reduced inflammatory cell infiltration and protection against inflammatory bone changes as measured by micro CT. In contrast, prophylactic deletion of FAP expressing cells led to a delayed onset of inflammatory arthritis, but did not impact on subsequent clinical severity. 

Conclusion: These data support a pathogenic role for a subset of FAP expressing FLS in inflammatory arthritis and provide a rationale for the selective targeting of FAP+ fibroblasts as a novel therapeutic approach.

<span” roman”=”Roman”” new=”New”><span” roman”=”Roman”” new=”New”><span” roman”=”Roman”” new=”New”>


Disclosure: A. P. Croft, None; J. Campos, None; A. Filer, None; F. Barone, None; C. Buckley, None.

To cite this abstract in AMA style:

Croft AP, Campos J, Filer A, Barone F, Buckley C. Selective Deletion of a Pathogenic Subset Synovial Fibroblasts Attenuates Synovial Inflammation [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/selective-deletion-of-a-pathogenic-subset-synovial-fibroblasts-attenuates-synovial-inflammation/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/selective-deletion-of-a-pathogenic-subset-synovial-fibroblasts-attenuates-synovial-inflammation/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology